<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01977456</url>
  </required_header>
  <id_info>
    <org_study_id>P50NS044283-13</org_study_id>
    <secondary_id>P50NS044283-13</secondary_id>
    <nct_id>NCT01977456</nct_id>
  </id_info>
  <brief_title>Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)</brief_title>
  <acronym>CLEAR-FDR</acronym>
  <official_title>Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arthur Pancioli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this trial is to determine if individuals with acute ischemic stroke
      treated with a full dose of IV recombinant tissue plasminogen activator (rt-PA) plus IV
      eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome
      than individuals treated with standard IV rt-PA alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke-Full
      Dose Regimen (CLEAR-FDR Stroke Trial) is a Phase II trial and part of the Specialized Program
      on Translational Research in Acute Stroke (SPOTRIAS). The overall goals of SPOTRIAS are to
      enhance delivery of acute stroke patient care and train acute stroke translational
      researchers.

      Stroke most often occurs when blood flow to the brain stops because it is blocked by a blood
      clot. When a blood clot blocks the blood supply to the brain, parts of the brain may not get
      enough blood and oxygen to survive. As a result, permanent brain damage can occur, which can
      affect a person's ability to walk, talk, and function independently. In order to reduce the
      risk of permanent damage, it is important to restore blood flow to the brain as quickly as
      possible.

      rt-PA, used alone, is already approved by the Food and Drug Administration (FDA) as treatment
      for patients with a stroke caused by blockage of an artery in the brain and when given within
      3 hours of the onset of stroke symptoms. Eptifibatide is also already FDA-approved as a
      treatment for blood clots causing heart attack. The investigational aspect of this study is
      the use of eptifibatide for a stroke victim in combination with rt-PA.

      The CLEAR Stroke Trial demonstrated that the combination of low dose rt-PA plus eptifibatide
      can be safely given to acute ischemic stroke patients within 3 hours of symptom onset.

      The CLEAR-ER Stroke Trial demonstrated that the combination of medium dose rt-PA plus
      eptifibatide can be safely given to acute ischemic stroke patients within 3 hours of symptom
      onset.

      The CLEAR-FDR Stroke Trial is designed to provide data concerning the risks when combining
      eptifibatide with full dose intravenous rt-PA in 30 acute ischemic stroke patients within 3
      hours of symptom onset.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Patients Who Experience Symptomatic Intracerebral Hemorrhage (sICH).</measure>
    <time_frame>within 36 hours after stroke onset</time_frame>
    <description>Any ICH related to a decline in neurologic status or the development of new neurologic symptoms which in the judgment of the clinical investigator was related to the ICH. Judgment of significant neurological decline was made by the local clinical investigator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Who Experience Any Intracerebral Hemorrhage (ICH).</measure>
    <time_frame>within 36 hours after stroke onset</time_frame>
    <description>Any ICH symptomatic (as defined above) or asymptomatic (that visualized on CT or MRI only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Who Develop Parenchymal Hemorrhage Types 1( PH-1) and 2 (PH-2).</measure>
    <time_frame>within 36 hours after stroke onset</time_frame>
    <description>Any parenchymal hemorrhage types PH-1 or PH-2 as visualized on CT</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The Number of Participants With Good Outcomes According to the Modified Rankin Score.</measure>
    <time_frame>90 days from the date of stroke onset</time_frame>
    <description>Modified Rankin score (mRS) dichotomized to good outcome (mRS 0-1 or return to baseline), poor outcome (all others including death). Results reported are good outcome.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Stroke</condition>
  <condition>Brain Infarction</condition>
  <arm_group>
    <arm_group_label>Eptifibatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eptifibatide</intervention_name>
    <description>IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.</description>
    <arm_group_label>Eptifibatide</arm_group_label>
    <other_name>Integrilin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a serious measurable neurological deficit on the NIH Stroke Scale
             due to focal brain ischemia.

          -  An NIH Stroke Scale score &gt;5 at the time the rt-PA is begun.

          -  Age: 18 through 85 years (i.e. candidates must have had their 18th birthday, but not
             had their 86th birthday).

          -  Intravenous rt-PA therapy must be initiated within 3 hours of onset of stroke
             symptoms.

        Exclusion Criteria:

          -  History of stroke in the past 3 months.

          -  Previous intra-cranial hemorrhage, neoplasm, subarachnoid hemorrhage, or arterial
             venous malformation.

          -  Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT scan is
             normal.

          -  Hypertension at time of treatment; systolic BP &gt; 185 or diastolic &gt; 110 mmHg or
             aggressive measures to lower blood pressure to below these limits are needed.

          -  Presumed septic embolus.

          -  Presumed pericarditis including pericarditis after acute myocardial infarction.

          -  Recent (within 30 days) surgery or biopsy of parenchymal organ.

          -  Recent (within 30 days) trauma, with internal injuries or ulcerative wounds.

          -  Recent (within 90 days) severe head trauma or head trauma with loss of consciousness.

          -  Any active or recent (within 30 days) serious systemic hemorrhage.

          -  Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; or
             oral anticoagulant therapy with International Normalized Ratio (INR) &gt; 1.7.

          -  Baseline lab values: positive urine pregnancy test, glucose &lt; 50 or &gt; 400 mg/dl,
             platelets &lt;100,000 /mm3, Hct &lt;25 %, or creatinine &gt; 4 mg/dl.

          -  Ongoing renal dialysis, regardless of creatinine.

          -  Subjects who received Low Molecular Weight heparins (such as Dalteparin, Enoxaparin,
             Tinzaparin) as deep vein thrombosis (DVT) prophylaxis or in full dose within the
             previous 24 hours.

          -  Subjects who received heparin or a direct thrombin inhibitor (such as bivalirudin,
             argatroban, or lepirudin) within 48 hours from screening must have had a normal
             partial prothrombin time (PTT).

          -  Subjects who received Factor Xa inhibitors (such as fondaparinux) or direct thrombin
             inhibitors (such as dabigatran) within the last 4 days.

          -  Arterial puncture at a non-compressible site or a lumbar puncture in the previous 7
             days.

          -  Seizure at onset of stroke.

          -  Pre-existing neurological or psychiatric disease that would confound the neurological
             or functional evaluations.

          -  Other serious, advanced, or terminal illness or any other condition that the
             investigator feels would pose a significant hazard to the patient if rt-PA or
             eptifibatide therapy were initiated.

          -  Patients whose peripheral venous access is so poor that they are unable to have two
             standard peripheral intravenous lines started.

          -  Current participation in another research drug treatment protocol. Patient cannot
             start another experimental agent until after 90 days.

          -  Informed consent is not or cannot be obtained.

          -  Any known history of amyloid angiopathy.

          -  High density lesion consistent with hemorrhage of any degree.

          -  Significant mass effect with midline shift.

          -  Large (more than 1/3 of the middle cerebral artery) regions of clear hypodensity on
             the baseline CT scan. Sulcal effacement and/or loss of grey-white differentiation
             alone are not contraindications for treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Opeolu Adeoye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Elizabeth Healthcare System Edgewood</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Healthcare Florence</name>
      <address>
        <city>Florence</city>
        <state>Kentucky</state>
        <zip>41042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Healthcare Ft. Thomas</name>
      <address>
        <city>Ft. Thomas</city>
        <state>Kentucky</state>
        <zip>41075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda North Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clear-fdr.org</url>
    <description>CLEAR-FDR Stroke Trial web site</description>
  </link>
  <results_reference>
    <citation>Adeoye O, Sucharew H, Khoury J, Vagal A, Schmit PA, Ewing I, Levine SR, Demel S, Eckerle B, Katz B, Kleindorfer D, Stettler B, Woo D, Khatri P, Broderick JP, Pancioli AM. Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial. Stroke. 2015 Sep;46(9):2529-33. doi: 10.1161/STROKEAHA.115.010260. Epub 2015 Aug 4.</citation>
    <PMID>26243231</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2013</study_first_posted>
  <results_first_submitted>October 23, 2015</results_first_submitted>
  <results_first_submitted_qc>October 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2015</results_first_posted>
  <last_update_submitted>December 16, 2015</last_update_submitted>
  <last_update_submitted_qc>December 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Arthur Pancioli</investigator_full_name>
    <investigator_title>sub investigator</investigator_title>
  </responsible_party>
  <keyword>acute ischemic stroke</keyword>
  <keyword>stroke</keyword>
  <keyword>rt-PA, thrombolytic</keyword>
  <keyword>t-PA</keyword>
  <keyword>recombinant tissue plasminogen activator</keyword>
  <keyword>Activase</keyword>
  <keyword>eptifibatide</keyword>
  <keyword>Integrilin</keyword>
  <keyword>fibrinolytic agents</keyword>
  <keyword>clot dissolving</keyword>
  <keyword>blood clot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Brain Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eptifibatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Eptifibatide</title>
          <description>All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.
Eptifibatide: IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eptifibatide</title>
          <description>All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.
Eptifibatide: IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.4" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>National Institutes of Health Stroke Scale Score (NIHSS)</title>
          <description>NIHSS score: A 43 point ordinal scale (0 to 42) measuring severity of stroke. 0 (no measurable effect), 42 (dead)</description>
          <units>score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" lower_limit="9" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Patients Who Experience Symptomatic Intracerebral Hemorrhage (sICH).</title>
        <description>Any ICH related to a decline in neurologic status or the development of new neurologic symptoms which in the judgment of the clinical investigator was related to the ICH. Judgment of significant neurological decline was made by the local clinical investigator</description>
        <time_frame>within 36 hours after stroke onset</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eptifibatide</title>
            <description>All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.
Eptifibatide: IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Who Experience Symptomatic Intracerebral Hemorrhage (sICH).</title>
          <description>Any ICH related to a decline in neurologic status or the development of new neurologic symptoms which in the judgment of the clinical investigator was related to the ICH. Judgment of significant neurological decline was made by the local clinical investigator</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Who Experience Any Intracerebral Hemorrhage (ICH).</title>
        <description>Any ICH symptomatic (as defined above) or asymptomatic (that visualized on CT or MRI only)</description>
        <time_frame>within 36 hours after stroke onset</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eptifibatide</title>
            <description>All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.
Eptifibatide: IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Who Experience Any Intracerebral Hemorrhage (ICH).</title>
          <description>Any ICH symptomatic (as defined above) or asymptomatic (that visualized on CT or MRI only)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Who Develop Parenchymal Hemorrhage Types 1( PH-1) and 2 (PH-2).</title>
        <description>Any parenchymal hemorrhage types PH-1 or PH-2 as visualized on CT</description>
        <time_frame>within 36 hours after stroke onset</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eptifibatide</title>
            <description>All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.
Eptifibatide: IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Who Develop Parenchymal Hemorrhage Types 1( PH-1) and 2 (PH-2).</title>
          <description>Any parenchymal hemorrhage types PH-1 or PH-2 as visualized on CT</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number of Participants With Good Outcomes According to the Modified Rankin Score.</title>
        <description>Modified Rankin score (mRS) dichotomized to good outcome (mRS 0-1 or return to baseline), poor outcome (all others including death). Results reported are good outcome.</description>
        <time_frame>90 days from the date of stroke onset</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eptifibatide</title>
            <description>All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.
Eptifibatide: IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Good Outcomes According to the Modified Rankin Score.</title>
          <description>Modified Rankin score (mRS) dichotomized to good outcome (mRS 0-1 or return to baseline), poor outcome (all others including death). Results reported are good outcome.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events are monitored through 90 days. Non-serious adverse events are monitored through day 3 or discharge</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eptifibatide</title>
          <description>All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.
Eptifibatide: IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemias nonhaemolytic and marrow depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrhythmias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Heart failures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic complications</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Glucose metabolism disorders (incl diabetes mellitus)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General system disorders NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic complications</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Glucose metabolism disorders (incl diabetes mellitus)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathies and bleeding diatheses (excl thrombocytopenic)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>White blood cell disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrhythmias</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal motility and defaecation conditions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gastrointestinal signs and symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections - pathogen unspecified</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte and fluid balance conditions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological disorders NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety disorders and symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary tract disorders NEC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urinary tract signs and symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Epidermal and dermal conditions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Skin vascular abnormalities</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased and nonspecific blood pressure disorders and shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vascular haemorrhagic disorders</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size and open design. Did not include endovascular therapy patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Opeolu Adeoye</name_or_title>
      <organization>University of Cincinnati</organization>
      <phone>513-558-3117</phone>
      <email>opeolu.adeoye@uc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

